| Entry |
|
|---|
| Name |
Valganciclovir hydrochloride (JAN/USP);
Valcyte (TN) |
|---|
| Product |
|
|---|
| Generic |
VALGANCICLOVIR (Ajanta Pharma Limited), VALGANCICLOVIR (American Health Packaging), VALGANCICLOVIR (AvPAK), VALGANCICLOVIR (Camber Pharmaceuticals), VALGANCICLOVIR (Cipla USA), VALGANCICLOVIR (Dr. Reddy's Laboratories Limited), VALGANCICLOVIR (Golden State Medical Supply), VALGANCICLOVIR (Major Pharmaceuticals), VALGANCICLOVIR (NorthStar Rx LLC), VALGANCICLOVIR (Safecor Health), VALGANCICLOVIR HYDROCHLORIDE FOR ORAL (Actavis Pharma), VALGANCICLOVIR HYDROCHLORIDE (Ajanta Pharma Limited), VALGANCICLOVIR HYDROCHLORIDE (Aurobindo Pharma Limited), VALGANCICLOVIR (AvKARE), VALGANCICLOVIR HYDROCHLORIDE (Dr. Reddy's Laboratories), VALGANCICLOVIR HYDROCHLORIDE (Mckesson Corporation DBA SKY Packaginng), VALGANCICLOVIR (Par Pharmaceutical) |
|---|
| Formula |
C14H22N6O5. HCl
|
|---|
| Exact mass |
390.1418
|
|---|
| Mol weight |
390.8226
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antiviral
DG02840 Herpesvirus DNA polymerase inhibitor
DG01937 Anti-cytomegalovirus agent
|
|---|
| Remark |
| Therapeutic category: | 6250 |
| Product (DG00649): | D03256<JP/US> |
|
|---|
| Efficacy |
Antiviral, DNA polymerase inhibitor |
|---|
| Disease |
Cytomegalovirus (CMV) retinitis [DS: H00368] |
|---|
| Comment |
Active form of prodrug: Ganciclovir [DR: D00333]
|
|---|
| Target |
Herpesvirus DNA polymerase [KO: K18964] |
|---|
| Interaction |
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05AB14 Valganciclovir
D03256 Valganciclovir hydrochloride (JAN/USP) <JP/US>
USP drug classification [BR:br08302]
Antivirals
Anti-cytomegalovirus (CMV) Agents
Valganciclovir
D03256 Valganciclovir hydrochloride (JAN/USP)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D03256 Valganciclovir hydrochloride (JAN/USP)
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03256
Prodrugs [br08324.html]
DG00649
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 26
1 C8y C 27.4400 -16.6600
2 C8y C 27.4400 -15.2600
3 N4y N 26.1800 -17.2200
4 N4x N 28.7700 -17.3600
5 N5x N 26.1100 -14.9100
6 C8y C 28.5600 -14.4900
7 C8x C 25.3400 -16.1000
8 C8y C 29.8900 -16.5900
9 N5x N 29.8900 -15.1200
10 O5x O 28.5600 -13.0900
11 N1a N 31.1500 -17.2200
12 C1b C 26.1800 -18.6200
13 O2a O 24.9900 -19.3200
14 C1c C 23.8000 -18.6200
15 C1b C 22.6100 -19.3200
16 C1b C 23.8000 -17.2200
17 O7a O 21.4200 -18.6900
18 C7a C 20.2300 -19.3200
19 C1c C 19.0400 -18.6900
20 C1c C 17.8500 -19.3200
21 O1a O 22.6100 -16.5900
22 O6a O 20.2300 -20.7900
23 C1a C 16.6600 -18.6900
24 C1a C 17.8500 -20.7900
25 N1a N 19.0400 -17.2200
26 X Cl 34.6500 -15.8900
BOND 26
1 1 2 2
2 1 3 1
3 1 4 1
4 2 5 1
5 2 6 1
6 3 7 1
7 4 8 1
8 6 9 1
9 6 10 2
10 8 11 1
11 5 7 2
12 8 9 2
13 3 12 1
14 12 13 1
15 13 14 1
16 14 15 1
17 14 16 1
18 15 17 1
19 17 18 1
20 18 19 1
21 19 20 1
22 16 21 1
23 18 22 2
24 20 23 1
25 20 24 1
26 19 25 1 #Down
|
|---|
